Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.
We have recently shown that non-viral gene therapy can stabilise the decline of lung function in patients with cystic fibrosis (CF). However, the effect was modest, and more potent gene transfer agents are still required. Fuson protein (F)/Hemagglutinin/Neuraminidase protein (HN)-pseudotyped lentiviral vectors are more efficient for lung gene transfer than non-viral vectors in preclinical models. In preparation for a first-in-man CF trial using the lentiviral vector, we have undertaken key tr...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Pubs id:
- Local pid:
- Deposit date:
- Copyright holder:
- Alton et al
- Copyright date:
This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record